Table 2.
Systemic lupus erythematosus disease manifestations and prescribed medications by sex, n (%)1
| Males (n=126) |
Females (n=1336) |
P values | |
|---|---|---|---|
| Cardiovascular disease manifestations | |||
| Any cardiovascular event 2 | 58 (46) | 442 (33) | 0.005 § |
| Myocardial infarction | 22 (18) | 102 (8) | <0.001§,† |
| Coronary artery disease with or without angina | 41 (33) | 292 (22) | 0.009§ |
| Limb claudication | ≤20 (≤16) | ≤20 (≤1.5) | N/A |
| Congestive heart failure | 25 (20) | 188 (14) | 0.10 |
| Peripheral arterial disease | ≤20 (≤16) | 47 (4) | N/A |
| Stroke | ≤20 (≤16) | 77 (6) | N/A |
| Other organ-specific manifestations | |||
| Lupus nephritis | 31 (25) | 235 (18) | 0.07 |
| End-stage renal disease | ≤20 (≤16) | 70 (5) | N/A |
| Antiphospholipid syndrome | 24 (19) | 172 (13) | 0.07 |
| Lupus pericarditis | ≤20 (≤16) | 56 (4) | N/A |
| Lupus lung disease | ≤20 (≤16) | 47 (4) | N/A |
| Raynaud’s phenomenon | ≤20 (≤16) | 241 (18) | N/A |
| SLE medication: Ever prescribed 3 | |||
| Mycophenolate mofetil or mycophenolic acid | 40 (32) | 328 (25) | 0.09 |
| Azathioprine | ≤20 (≤16) | 253 (19) | N/A |
| Cyclophosphamide (oral or intravenous) | ≤20 (≤16) | 45 (3) | N/A |
| Methotrexate | 29 (23) | 324 (24) | 0.84 |
| Tacrolimus | ≤20 (≤16) | 157 (12) | N/A |
| Rituximab | ≤20 (≤16) | 84 (6) | N/A |
| Belimumab | ≤20 (≤16) | 108 (8) | N/A |
SLE: Systemic lupus erythematosus; N/A: not applicable
Designates statistical significance at alpha level 0.05
Designates statistical significance at Bonferroni adjusted alpha level of 0.002 (25 simultaneous tests)
Data summarized as n (%); according to the All of Us Research Program data and statistics dissemination policy, cell values and aggregate statistics that correspond to 1 to 20 participants are obscured to protect participant privacy. In these cases, P values are designated as N/A.
Any cardiovascular event includes myocardial infarction, coronary artery disease with or without angina, limb claudication, congestive heart failure, peripheral arterial disease, stroke, undergoing percutaneous transluminal coronary angioplasty, or undergoing coronary artery bypass grafting
Participant was considered to have ever been prescribed a specific medication or class if there was a past or current prescription documented in the electronic health record for that medication